ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Binghe Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4195-337X; OpenAlex author ID A5008098651. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 1 trial · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 1

Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. Co-author DOI 10.1016/j.canlet.2026.218331 ↗

Trials 1

A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours Principal investigator NCT03658070 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yumeng Hu · 1 shared paper, 2026 · strength 0.27
- Paper Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. DOI 10.1016/j.canlet.2026.218331 ↗
Shaobo Zhang · 1 shared paper, 2026 · strength 0.27
- Paper Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. DOI 10.1016/j.canlet.2026.218331 ↗
Mingyang Liu · 1 shared paper, 2026 · strength 0.27
- Paper Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. DOI 10.1016/j.canlet.2026.218331 ↗
Haoran Qi · 1 shared paper, 2026 · strength 0.27
- Paper Cancer-associated fibroblasts promote immune evasion in pancreatic cancer via miR-181b-5p/STING/LGALS1 pathway. DOI 10.1016/j.canlet.2026.218331 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.